ECL 131.33 Updated: 09-24-2017 $ECL Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
34
ECL 131.33 Updated: 09-24-2017 $ECL
Last Trade: 9/22/2017

Last 131.33   - 
Open 131.00
Previous Close 131.33
Day High / Low 131.44 / 130.74
Year High / Low 134.89 / 110.65
Volume 748,781
Projected Volume 748781 (79%)
# of Trades / Projected 3,378 / 3,378
Dividend / Yield 1.48 / 1.13%
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle BULLISH
Volatility Today LOW
Volatility Yesterday LOW
Price Relativity
From 40 Day High 99%
From 80 Day High 98%
From 150 Day High 98%
From 40 Day Low 101%
From 80 Day Low 101%
From 150 Day Low 107%
Pivot Analysis
Price Pivot $ 131.17
Day Resistance 1 $ 131.60
Day Support 1 $ 130.90
Day Resistance 2 $ 131.87
Day Support 2 $ 130.47
Consolidations
Short Term YES
Medium Term NO
Long Term YES
Volume Indicators
20 Day Avg Vol 953,081
Today / 20 Day Avg Vol BELOW
150 Day Avg Vol 932,127
Today / 150 Day Avg Vol BELOW
Abnormal Volume NO
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bearish
100 Day Trend bullish
Stochastics bearish
RSI bearish
MACD bearish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bearish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today LOW
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility INCREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Palisade Bio Launches PALI-2108 Study to Combat Crohn’s Disease

Updated Category News Views 142

Exciting Developments in Crohn’s Disease Treatment Today marks a pivotal point as Palisade Bio, Inc. (NASDAQ: PALI), a dynamic clinical-stage biopharmaceutical firm, undertakes a groundbreaking step in medical research by announcing the commencement of patient dosing in their Phase 1b clinical trial. This study is focused on PALI-2108, a novel therapeutic designed...

Continue Reading
Discover How Your $100 Investment in TD Synnex Has Grown

Updated Category News Views 126

Understanding the Growth of Your Investment in TD Synnex Investing in stocks can often feel like navigating a complex maze, especially when evaluating potential growth over time. One standout in the tech industry is TD Synnex (NASDAQ: SNX), a company that has consistently outperformed benchmark indices. Over the past five years, TD Synnex has achieved an annualized return...

Continue Reading
Castor Maritime Inc. Completes Successful Sale and Leaseback

Updated Category News Views 170

Castor Maritime Inc. Completes Successful Sale and Leaseback Castor Maritime Inc. (NASDAQ: CTRM), a versatile player in the global shipping and energy sector, recently announced an exciting development. The company successfully concluded a significant sale and leaseback transaction for its vessel, the M/V Magic Thunder, an impressive Kamsarmax bulk carrier that was built...

Continue Reading
Yamaha's Partnership with Locally Enhances Dealer Collaboration

Updated Category News Views 153

Yamaha Expands Dealer Network with Innovative Omnichannel Solutions Yamaha, a renowned global leader in musical instruments and audio solutions, has recently announced a strategic partnership with Locally. This collaboration aims to elevate the shopping experience for consumers and to strengthen relationships with local retailers. This initiative is particularly...

Continue Reading
POET Technologies Celebrates AI Award Win at Global Tech Awards

Updated Category News Views 73

POET Technologies' Landmark Achievement in Artificial Intelligence POET Technologies Inc. (TSX Venture: PTK; NASDAQ: POET), known for its groundbreaking work with the POET Optical Interposer™, has recently been honored with the title of "Best in Artificial Intelligence" at the Global Tech Awards 2024. This prestigious recognition was announced following the awards...

Continue Reading